DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) is set to present four significant abstracts at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, scheduled for October 23-25, 2024, in Barcelona, Spain. This prestigious event will feature Aprea’s progress in developing DNA damage response (DDR) inhibitors, highlighting promising advancements in cancer treatment.
Oren Gilad, Ph.D., President and CEO of Aprea, expressed enthusiasm about the opportunity to share their progress with a global audience. “We are very pleased to have these posters featured at the upcoming EORTC-NCI-AACR Symposium, showcasing the ongoing progress in our oncology pipeline of DDR inhibitors,” he stated. Dr. Gilad emphasized the importance of this platform in presenting updates on their clinical candidates APR-1051 and ATRN-119.
The symposium will feature both clinical and preclinical presentations from Aprea. Among the clinical highlights is a study on APR-1051, a WEE1 inhibitor, scheduled for presentation on October 23. Another key study focuses on ATRN-119, a novel macrocyclic ATR inhibitor, which will be discussed on October 25. Both presentations aim to provide insights into the safety and efficacy of these treatments for cancer-associated gene alterations and advanced solid malignancies, respectively.
Preclinical findings will also be presented on October 25, showcasing the characteristics of APR-1051 and the development of macrocyclic ATR inhibitors. These presentations underscore Aprea’s commitment to pioneering effective cancer therapies.
Attendees and interested parties can access copies of the posters on Aprea’s website following the symposium, offering further insights into their groundbreaking work.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.